---
title: "Hibiya Engineering Releases Q3 FY2025 Fact Book on Key Financial Trends"
description: "Hibiya Engineering, Ltd. has released its Q3 FY2025 Fact Book, detailing key financial trends including orders received, net sales, and segment information. This disclosure aims to enhance transparenc"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275399453.md"
published_at: "2026-02-10T03:57:46.000Z"
---

# Hibiya Engineering Releases Q3 FY2025 Fact Book on Key Financial Trends

> Hibiya Engineering, Ltd. has released its Q3 FY2025 Fact Book, detailing key financial trends including orders received, net sales, and segment information. This disclosure aims to enhance transparency regarding the company's financial health and operational performance. Analysts currently rate the stock as a Buy with a price target of Yen5750.00. Hibiya Engineering operates in the engineering and construction sector, providing insights into its performance through consolidated financial indicators.

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Hibiya Engineering,Ltd. ( (JP:1982) ).

Hibiya Engineering, Ltd. has released a fact book for the third quarter of the fiscal year ending March 31, 2026, providing trends in major management indicators on a consolidated basis. The materials highlight movements in orders received, net sales, the balance sheet, the statement of income, and segment information, giving investors and stakeholders an overview of the company’s financial health and business performance during the period.

By disclosing these trends, the company aims to enhance transparency around its operational momentum and financial structure. The focus on consolidated data and segment information suggests attention to both overall corporate performance and the contribution of individual business segments, which may be used by analysts to assess growth trajectories and risk profiles.

The most recent analyst rating on (JP:1982) stock is a Buy with a Yen5750.00 price target. To see the full list of analyst forecasts on Hibiya Engineering,Ltd. stock, see the JP:1982 Stock Forecast page.

**More about Hibiya Engineering,Ltd.**

Hibiya Engineering, Ltd. appears to be a Japanese company operating in the engineering and construction-related field, given its focus on orders received, net sales, balance sheet, and segment information on a consolidated basis. The company likely provides engineering or infrastructure-related services and reports its performance through detailed financial and operational indicators for stakeholders.

**Average Trading Volume:** 33,539

**Technical Sentiment Signal:** Buy

**Current Market Cap:** Yen116.9B

Learn more about 1982 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [1982.JP - Hibiya Engineering,Ltd.](https://longbridge.com/en/quote/1982.JP.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| TABLE-Hibiya Engineering -2025/26 parent forecast | Feb 10 (Reuters) -Hibiya Engineering LtdPARENT- ONLY EARNINGS ESTIMATES(in billions of yen unless specified) Full Year t | [Link](https://longbridge.com/en/news/275397226.md) |
| New Buy Rating for Gujarat Fluorochemicals Ltd. (FLUOROCHEM), the Basic Materials Giant | In a report released yesterday, from ICICI Securities maintained a Buy rating on Gujarat Fluorochemicals Ltd., with a pr | [Link](https://longbridge.com/en/news/276009682.md) |
| Komatsu Ltd. Announces Board Changes, Effective from April 1, 2026 | Komatsu Ltd. announced board changes effective April 1, 2026. Mr. Taisuke Kusaba has been appointed as Representative Di | [Link](https://longbridge.com/en/news/276050039.md) |
| Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy | Eisai Co., Ltd. has received orphan drug designation from Japan's Ministry of Health for its novel orexin 2 receptor ago | [Link](https://longbridge.com/en/news/276045347.md) |
| Sumitomo Forestry Co., Ltd. Provides Dividend Guidance for the Full Year Ending December 31, 2026 | Sumitomo Forestry Co., Ltd. provided dividend guidance for the fiscal year ending December 31, 2026. For the full year,  | [Link](https://longbridge.com/en/news/275925327.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.